Will Psilocybin Be FDA-Approved? (2026 Odds & Timeline)
A tracked, falsifiable answer from OOTWOracle · updated August 17, 2026
Almost certainly not in 2026. As of August 17, 2026, OOTWOracle puts it at 80% that vA psilocybin trials show sign-up info only — no results yet (resolves 2026-10-24). Psilocybin remains Schedule I; the FDA has approved no psilocybin product, and the nearest realistic path is a REMS-gated approval that is not expected this year.
Psilocybin — the active compound in psychedelic mushrooms — is being studied for treatment-resistant depression and other conditions, but studying a drug and approving it are different milestones. Approval requires the FDA to clear a specific product after Phase 3 trials, and it stays Schedule I under the DEA until that happens. Here is where the evidence actually points right now.
Current odds on this question
| Oracle odds | Prediction (falsifiable) | Resolves |
|---|
| 80% | VA psilocybin trials show sign-up info only — no results yet | 2026-10-24 |
| 75% | New psilocybin research papers will say 'we need more research' not 'use this now' | 2026-10-10 |
| 74% | VA's mushroom therapy trials will track safety, not results, by year-end | 2026-11-30 |
| 74% | Under-skin ketamine study will report safety only, no approval impact | 2026-11-30 |
| 72% | VA psilocybin news won't give COMPASS a new FDA boost | 2026-11-13 |
Every row is a public, dated, falsifiable prediction — scored against a written resolution rule when the date arrives. Methodology & hit-rate: the track record.
Frequently asked
Is psilocybin FDA-approved right now?
No. As of August 17, 2026, no psilocybin product has FDA marketing approval, and it remains a Schedule I controlled substance federally.
Could psilocybin be approved in 2026?
It is unlikely. The Oracle's current odds favor no full approval in 2026; the most plausible near-term route is a tightly REMS-gated approval that is not expected this calendar year.
What would have to happen first?
A positive Phase 3 program, an accepted New Drug Application, and an FDA decision — followed by DEA rescheduling of the specific approved product out of Schedule I.
How is this odds number produced?
A multi-agent simulation scores ~150 daily signals (PubMed, ClinicalTrials.gov, Congress.gov, market and press data) into calibrated probabilities, each with a written resolution rule that is checked publicly.